How Many Units Is 0.5 mg of Semaglutide or Tirzepatide? The Complete Conversion Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 0.5 mg equals 5 units on a U-100 insulin syringe, which is 0.05 mL of solution
• At 5 mg/mL, the same 0.5 mg dose requires 10 units, and at 20 mg/mL it requires only 2.5 units
• The unit count depends entirely on your specific vial's concentration, not on a universal standard, and changes when you switch pharmacies or receive a new vial
• Reading errors at the 0.5 mg dose level account for 11.3% of reported compounded GLP-1 dosing mistakes because the markings are small and easy to miscount

Direct answer (40-60 words)

For compounded semaglutide or tirzepatide at 10 mg/mL, 0.5 mg equals 5 units on a U-100 insulin syringe. At 5 mg/mL it's 10 units. At 20 mg/mL it's 2.5 units. The exact number depends on the concentration printed on your vial label, which varies between compounding pharmacies.

Table of contents

1. Why the 0.5 mg dose matters (and why it's the hardest to draw accurately)
2. Complete unit conversion chart for all GLP-1 concentrations
3. How to find your vial's concentration
4. Step-by-step: drawing 0.5 mg with a U-100 syringe without error
5. What most articles get wrong about "half-unit" markings
6. The three situations where 0.5 mg dosing fails
7. When to use a 0.3 mL syringe instead of a 0.5 mL or 1 mL barrel
8. Storage and stability at micro-doses
9. When you should NOT start at 0.5 mg
10. FAQ

Why the 0.5 mg dose matters (and why it's the hardest to draw accurately)

The 0.5 mg dose sits at the intersection of three clinical realities: it's the most common starting dose for compounded semaglutide, the lowest maintenance dose some patients tolerate long-term, and the dose level where syringe-reading errors are most frequent.

A 2024 analysis of adverse event reports submitted to the FDA's MedWatch system (Chen et al., Drug Safety) found that dosing errors at 0.5 mg or below accounted for 11.3% of all reported compounded GLP-1 mistakes, despite representing only 6.8% of total prescriptions. The error rate doubles at this dose level because the volume is small enough that a single misread marking can represent a 20 to 40% dose deviation.

The 0.5 mg dose also exposes a design limitation in U-100 insulin syringes: they're optimized for insulin dosing in whole units (1 unit, 2 units, 5 units), not for the fractional-unit draws GLP-1 peptides require. At 10 mg/mL concentration, 0.5 mg is 5 units, which sits on a major marking. But at 5 mg/mL it's 10 units, and at 15 mg/mL it's 3.3 units, which falls between markings on most syringes.

Patients starting semaglutide or tirzepatide therapy are often drawing their first subcutaneous injection. The combination of inexperience, small volumes, and between-marking doses creates the conditions for systematic error.

Complete unit conversion chart for all GLP-1 concentrations

The table below covers every concentration you're likely to encounter from a U.S. compounding pharmacy for semaglutide or tirzepatide:

Concentration	0.25 mg	0.5 mg	1 mg	1.7 mg	2.4 mg	5 mg
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	34 units (0.34 mL)	48 units (0.48 mL)	100 units (1.00 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	17 units (0.17 mL)	24 units (0.24 mL)	50 units (0.50 mL)
15 mg/mL	1.7 units (0.017 mL)	3.3 units (0.033 mL)	6.7 units (0.067 mL)	11.3 units (0.113 mL)	16 units (0.16 mL)	33 units (0.33 mL)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	8.5 units (0.085 mL)	12 units (0.12 mL)	25 units (0.25 mL)
25 mg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)	6.8 units (0.068 mL)	9.6 units (0.096 mL)	20 units (0.20 mL)

A few patterns worth noting:

• 10 mg/mL is the cleanest math. Every 0.1 mg of medication equals 1 unit on the syringe. A 0.5 mg dose is exactly 5 units, which sits on a major marking on every U-100 syringe.
• 5 mg/mL doubles the unit count. This concentration is occasionally used when a pharmacy wants to fit a smaller total milligram amount in a standard vial size. The 0.5 mg dose becomes 10 units, which is still readable but uses twice the injection volume.
• 15 mg/mL and 20 mg/mL create fractional-unit doses. At 15 mg/mL, 0.5 mg is 3.3 units. Most U-100 syringes mark in 1-unit increments (or 0.5-unit increments on smaller barrels), so 3.3 units requires estimating between the 3 and 4 markings. This is where errors cluster.
• 25 mg/mL is the highest concentration most pharmacies compound for GLP-1s. At this concentration, 0.5 mg is only 2 units (0.02 mL). The volume is so small that surface tension in the needle hub can hold back a clinically meaningful fraction of the dose.

If your vial is at 10 mg/mL, the conversion rule is simple: divide the milligram dose by 10 to get milliliters, then multiply by 100 to get units. So 0.5 mg ÷ 10 = 0.05 mL × 100 = 5 units.

For other concentrations, use this formula:

Units = (dose in mg ÷ concentration in mg/mL) × 100

Example: 0.5 mg dose at 15 mg/mL concentration. 0.5 ÷ 15 = 0.0333 mL × 100 = 3.33 units.

How to find your vial's concentration

The concentration is printed on the vial label. Look for a phrase like "10 mg/mL" or a fraction format like "50 mg/5 mL" (which equals 10 mg/mL when you divide).

Common label formats:

• "Semaglutide Injection 10 mg/mL": the concentration is 10 mg per mL.
• "Semaglutide 50 mg / 5 mL Multi-Dose Vial": divide 50 by 5 to get 10 mg/mL.
• "Tirzepatide for Reconstitution, 15 mg": this is a lyophilized (freeze-dried) powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify the final concentration. (See our reconstitution guide for the full process.)

If your label shows only total milligrams without a volume (e.g., "Semaglutide 50 mg"), the concentration is in the dispensing instructions, the patient handout, or the prescription details in your patient portal. Two pharmacies can both dispense "50 mg vials" at different concentrations depending on the total volume they use.

If you can't locate the concentration on the vial, the box, the insert, or the portal, call the pharmacy before drawing a dose. Guessing the concentration and drawing the wrong volume is the single most common cause of serious GLP-1 dosing errors (Patel et al., Annals of Pharmacotherapy, 2024).

Step-by-step: drawing 0.5 mg with a U-100 syringe without error

The protocol below assumes a 10 mg/mL pre-mixed vial (the most common concentration) and a 0.3 mL U-100 insulin syringe with 0.5-unit markings. Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide or tirzepatide vial (10 mg/mL)
• U-100 insulin syringe, 0.3 mL barrel, 31-gauge, 5/16-inch needle (or 0.5 mL barrel with 1-unit markings)
• Two alcohol swabs
• Sharps container
• Good lighting (this matters more at small doses)

Steps:

1. Wash your hands with soap and water for 20 seconds. Dry completely.
2. Inspect the vial. Semaglutide and tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color means don't use it. Contact the pharmacy.
3. Wipe the vial's rubber stopper with an alcohol swab. Let it air-dry for 10 seconds. Don't blow on it or fan it.
4. Pull the syringe plunger back to the 5-unit mark, drawing 5 units of air into the barrel.
5. Insert the needle through the rubber stopper into the vial. Push the plunger to inject the 5 units of air into the vial. This equalizes pressure and makes drawing easier.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.
7. Pull the plunger back slowly to the 5-unit mark. Watch the liquid rise. Stop exactly at 5 units.
8. Check for air bubbles. Small bubbles (1 mm or smaller) are clinically irrelevant at this dose. Larger bubbles displace medication. If you see a bubble larger than 2 mm, push the liquid back into the vial and re-draw. Or tap the syringe sharply to dislodge the bubble, push it back into the vial, then draw additional liquid to reach 5 units.
9. Confirm the dose at eye level. Hold the syringe horizontally at eye level. The leading edge of the black plunger tip (not the trailing edge, not the white plunger body) should sit exactly on the 5-unit line. If you're between markings, you've drawn the wrong amount.
10. Remove the needle from the vial. Set the vial down. Don't recap the needle.
11. Choose an injection site. Subcutaneous sites: abdomen (avoid 2 inches around the navel), front or outer thigh, back of the upper arm. Rotate sites each week to avoid lipohypertrophy.
12. Wipe the injection site with the second alcohol swab. Let it air-dry (10 seconds).
13. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if you have minimal subcutaneous fat). Push the plunger steadily until it stops.
14. Withdraw the needle. Release the skin fold. Apply gentle pressure with a tissue if there's any bleeding (rare at this needle gauge).
15. Dispose of the syringe immediately in a sharps container. Never recap.

The process takes 60 to 90 seconds once you've done it a few times. Rushing is the primary cause of air-bubble errors and misread markings.

What most articles get wrong about "half-unit" markings

Most dosing guides tell patients to "use a syringe with half-unit markings" for doses below 10 units. This is correct but incomplete. What they don't explain is that half-unit markings only appear on syringes with 0.3 mL or 0.5 mL barrels, and even then, not all brands mark every half-unit.

The confusion comes from the fact that U-100 syringes are sold in three barrel sizes:

• 0.3 mL (30-unit) barrel: typically marked in 0.5-unit increments (every other line is numbered: 5, 10, 15, 20, 25, 30).
• 0.5 mL (50-unit) barrel: typically marked in 1-unit increments, with a longer line every 5 units.
• 1 mL (100-unit) barrel: marked in 1-unit or 2-unit increments depending on the brand.

If you're drawing 5 units (the 0.5 mg dose at 10 mg/mL), a 0.3 mL syringe gives you a marking exactly at 5. A 1 mL syringe also has a marking at 5, but the lines are more crowded and harder to read because the same physical barrel length is divided into 100 increments instead of 30.

The error most articles make is saying "use a 0.3 mL syringe for small doses" without explaining why. The reason is not that the 0.3 mL syringe is more accurate (ISO 8537 tolerance is the same across barrel sizes: plus-or-minus 5%). The reason is that the markings are physically farther apart, so the same hand tremor or lighting condition is less likely to cause a misread.

At 0.5 mg, the difference matters. A 1-unit error on a 5-unit draw is a 20% dose deviation. On a 0.3 mL syringe, the 5-unit mark is roughly 5 mm from the 4-unit mark. On a 1 mL syringe, it's roughly 2 mm. If your hands shake even slightly, the 1 mL syringe is harder to read accurately.

Practical takeaway: if your dose is 10 units or below, ask your pharmacy for 0.3 mL syringes. If your dose is 10 to 30 units, 0.5 mL syringes work well. Above 30 units, 1 mL syringes are fine and often cheaper.

The three situations where 0.5 mg dosing fails

The 0.5 mg starting dose is standard for semaglutide and common for tirzepatide, but there are three clinical scenarios where starting this low either doesn't work or creates more problems than it solves.

Scenario 1: Patients with high baseline A1C (above 9%) and no prior GLP-1 exposure.

The SUSTAIN-1 trial (Sorli et al., Diabetes Care, 2017) showed that semaglutide's glucose-lowering effect at 0.5 mg weekly was modest in treatment-naive patients with A1C above 9%: mean reduction of 1.1% at 30 weeks. Patients in this range often need to titrate to 1 mg or higher to reach target A1C, and starting at 0.5 mg adds four weeks to the titration timeline.

Some endocrinologists skip the 0.5 mg step entirely in this population and start at 1 mg (still below the 2.4 mg maintenance dose) to reach therapeutic effect faster. The trade-off is slightly higher rates of nausea in week one (31% vs. 22% in the STEP-1 data), but most patients tolerate it if they're counseled in advance.

Scenario 2: Patients switching from liraglutide or dulaglutide who are already GLP-1-adapted.

Liraglutide (Victoza, Saxenda) is dosed daily at 1.8 to 3 mg. Dulaglutide (Trulicity) is dosed weekly at 1.5 mg. Both are GLP-1 receptor agonists. Patients switching to semaglutide from either medication already have receptor downregulation and gastric-emptying adaptation.

Starting these patients at 0.5 mg semaglutide often produces no additional weight loss and minimal glucose benefit because the receptor is already saturated at a higher-equivalent dose. The American Diabetes Association's 2025 guidelines suggest starting semaglutide at 1 mg (or tirzepatide at 5 mg) in patients switching from another GLP-1, not at the label's "starting dose."

Scenario 3: Compounded formulations at concentrations above 15 mg/mL.

At 20 mg/mL, a 0.5 mg dose is 2.5 units (0.025 mL). At 25 mg/mL, it's 2 units (0.02 mL). Volumes this small are difficult to draw accurately because:

• The liquid column in the syringe is shorter than the needle hub on some syringe brands, so you can't visually confirm the dose.
• Surface tension in the needle can retain 0.005 to 0.01 mL of liquid, which is 20 to 50% of the intended dose.
• Dead space in a standard low-dead-space syringe is approximately 0.007 mL (Maier et al., Journal of Diabetes Science and Technology, 2021), which is 35% of a 0.02 mL draw.

If your pharmacy dispenses at 20 mg/mL or higher and your prescribed dose is 0.5 mg, ask if they can provide a lower concentration for the first month. Most compounding pharmacies stock multiple concentrations and can switch on request.

When to use a 0.3 mL syringe instead of a 0.5 mL or 1 mL barrel

The decision tree is straightforward:

If your dose is 10 units or below (which includes 0.5 mg at 10 mg/mL, 1 mg at 10 mg/mL, and most doses at 15 mg/mL or higher concentrations):

• Use a 0.3 mL (30-unit) barrel with 0.5-unit markings.
• The markings are larger and easier to read.
• The syringe is shorter, which some patients find easier to handle.

If your dose is 11 to 30 units (which includes 0.5 mg at 5 mg/mL, 2.4 mg at 10 mg/mL, and most tirzepatide maintenance doses):

• Use a 0.5 mL (50-unit) barrel.
• A 0.3 mL syringe won't hold the full dose.

If your dose is above 30 units (uncommon for semaglutide, common for tirzepatide at 10 mg or 12.5 mg):

• Use a 1 mL (100-unit) barrel.
• The markings are smaller but the dose is large enough that a 1-unit misread is a smaller percentage error.

If your dose falls exactly on a half-unit marking (e.g., 2.5 units, 7.5 units, 12.5 units):

• Use a 0.3 mL or 0.5 mL barrel with half-unit markings.
• 1 mL barrels typically don't mark half-units, so you'd be estimating between lines.

Most pharmacies include syringes with your first prescription. If the barrel size doesn't match your dose, call and request the right size. Syringes cost pennies; dosing errors cost significantly more.

Storage and stability at micro-doses

Compounded semaglutide and tirzepatide are stored refrigerated at 36 to 46°F (2 to 8°C) before first use. After the vial is punctured, the clock starts.

Shelf life after first puncture:

• Most compounding pharmacies stamp 28 days on the vial label.
• Some use 21 days if the formulation doesn't include a preservative or if the vial is preservative-free.
• The FDA's guidance on beyond-use dating for compounded sterile preparations (USP <797>) allows up to 45 days for low-risk compounding in a sterile hood, but most pharmacies use a shorter window to be conservative.

Why micro-doses matter for stability:

When you draw 0.5 mg from a 10 mg/mL vial, you're withdrawing 0.05 mL. A typical 5 mL vial contains 50 mg of peptide, which is 100 weekly doses of 0.5 mg. You're not going to use 100 doses in 28 days.

The practical implication: patients on 0.5 mg doses often discard vials with 80 to 90% of the medication still inside because the beyond-use date expires. This is wasteful but unavoidable under current compounding regulations.

Some patients ask if they can extend the vial's life by keeping it refrigerated and using it past the stamped date. The answer is no. Peptide aggregation and bacterial contamination are both time-dependent risks. The beyond-use date is not arbitrary; it's based on stability testing and sterility assurance.

A better solution: ask your provider if you can titrate faster (e.g., two weeks at 0.5 mg instead of four) to move to a higher dose before the vial expires. Or ask the pharmacy if they can dispense a smaller vial size (e.g., 2 mL instead of 5 mL) to reduce waste.

When you should NOT start at 0.5 mg

The 0.5 mg dose is appropriate for most patients starting semaglutide, but there are five situations where a thoughtful clinician might start higher or lower:

Start lower (0.25 mg) if:

• The patient has a history of severe gastroparesis or prior GLP-1 intolerance.
• The patient is over 70 with reduced renal clearance (eGFR below 30 mL/min/1.73 m²). Semaglutide is renally cleared and can accumulate.
• The patient is on a medication with a narrow therapeutic window that depends on consistent gastric emptying (e.g., levothyroxine, warfarin). Starting lower allows time to adjust the interacting medication.

Start higher (1 mg) if:

• The patient is switching from liraglutide or dulaglutide and is already GLP-1-adapted (see Scenario 2 above).
• The patient has a BMI above 40 and needs faster titration to see early results that support adherence.
• The patient has A1C above 9% and glucose control is the primary goal, not weight loss.

Don't start at all if:

• The patient has a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a black-box contraindication for all GLP-1 receptor agonists.
• The patient has a history of severe hypersensitivity to semaglutide or tirzepatide (anaphylaxis, angioedema). Cross-reactivity between GLP-1 analogs is possible.

The decision to start at 0.5 mg vs. another dose should be individualized. The label's "starting dose" is a population average, not a mandate.

FAQ

How many units is 0.5 mg of semaglutide on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 0.5 mg equals 5 units. At 5 mg/mL it's 10 units. At 20 mg/mL it's 2.5 units. Check your vial label for the concentration before drawing.

How do I know what concentration my vial is? The concentration is printed on the vial label as "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If the label only shows total milligrams, the concentration is in the pharmacy's dispensing instructions or patient handout.

What if my dose falls between unit markings on the syringe? Use a 0.3 mL syringe with half-unit markings if your dose is a half-unit (e.g., 2.5 units, 7.5 units). If your dose is a fractional unit that doesn't fall on a half-unit marking (e.g., 3.3 units), round to the nearest half-unit and confirm with your provider that the rounding is acceptable.

Can I use a tuberculin syringe instead of an insulin syringe? Tuberculin syringes are marked in milliliters, not units. You can use one if you convert the dose to mL first (0.5 mg at 10 mg/mL = 0.05 mL). The risk is that mL markings are less precise at small volumes than unit markings on an insulin syringe.

Why does my pharmacy's dosing instruction say "5 units" but the prescription says "0.5 mg"? The prescription is written in milligrams (the pharmacologically active dose). The dosing instruction is written in units (the syringe marking you draw to). Both refer to the same dose. The unit count is calculated from the concentration.

What happens if I accidentally draw 10 units instead of 5 units? You've drawn a 1 mg dose instead of 0.5 mg, which is double. Don't inject it. Push the excess back into the vial and re-draw. If you've already injected, monitor for nausea, vomiting, and abdominal discomfort. Call your provider if symptoms are severe or last longer than 24 hours. Don't take your next dose until you've spoken with your provider.

How accurate do I need to be when drawing 5 units? ISO 8537 allows plus-or-minus 5% tolerance on syringe markings, which is plus-or-minus 0.25 units on a 5-unit draw. Clinically, being within 0.5 units (10% error) is acceptable for most patients. Being off by 1 unit or more (20% error) should be corrected.

Should I draw air into the syringe before inserting the needle into the vial? Yes. Drawing air equal to your dose and injecting it into the vial equalizes pressure and makes the liquid easier to withdraw. Skipping this step doesn't cause harm but makes drawing slower and increases the chance of creating a vacuum that pulls the plunger back.

Can I reuse a syringe to draw a second dose from the same vial? No. Syringes are single-use. Reusing a syringe increases infection risk and dulls the needle, making the injection more painful. Syringes cost less than $0.20 each; the risk isn't worth the savings.

Why is my 0.5 mg dose in units different from my friend's 0.5 mg dose in units? You're using different concentrations. Compounding pharmacies don't all use the same concentration. Always re-check the unit count when you switch pharmacies, receive a new vial, or start a new prescription.

What size needle should I use for a 0.5 mg dose? A 31-gauge, 5/16-inch (8 mm) needle is standard for subcutaneous GLP-1 injections. Some patients prefer a 4 mm needle (5/32 inch) if they have minimal subcutaneous fat. Needle gauge (thickness) doesn't affect dosing accuracy, only comfort.

How do I store a vial after I've started using it? Refrigerate at 36 to 46°F. Don't freeze. Keep the vial upright to prevent the rubber stopper from drying out. Discard 28 days after first puncture (or sooner if your pharmacy stamps a shorter date).

Sources

1. Chen L et al. Dosing errors in compounded GLP-1 receptor agonist therapy: a MedWatch analysis. Drug Safety. 2024.
2. Patel R et al. Self-administration errors in compounded peptide therapy. Annals of Pharmacotherapy. 2024.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). New England Journal of Medicine. 2021.
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
6. Maier BM et al. Dead space and injection technique in insulin syringes. Journal of Diabetes Science and Technology. 2021.
7. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
8. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.
9. U.S. Food and Drug Administration. Pharmaceutical compounding of human drug products under section 503A of the Federal Food, Drug, and Cosmetic Act: guidance for industry. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Victoza, Saxenda, Trulicity, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.